BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?
First Live Meeting Since 2019 Begins In San Diego
News and views from day one of the BIO annual meeting include reflections on how the biopharma industry is adjusting to current conditions. EY's annual Beyond Borders reports predicts continued success based on past performance, CBRE tracks how the life science industry is spreading out, and Organon's CEO discusses the company's biosimilars deal with Henlius.
You may also be interested in...
CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year
A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.
BIO 2022: ‘Limitless’ Innovation Is Harder With Limited Cash
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.